Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 57Burkitt Lymphoma 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Mantle-Cell 6Leukemia, Biphenotypic, Acute 6Immunoglobulin Light-chain Amyloidosis 5Smoldering Multiple Myeloma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Plasmacytoma 3Neoplasm Metastasis 3Lung Neoplasms 3Leukemia, Plasma Cell 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Down Syndrome 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Blast Crisis 3Vomiting 2Recurrence 2Ovarian Neoplasms 2Neoplasms 2Nausea 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Lenalidomide 2Dexamethasone 2ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × POEMS Syndrome × auricularum × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡